Bergal SR: Main Uses and Benefits

Bergal SR is a medication formulated to address specific chronic conditions that require consistent therapeutic management. The SR designation (Sustained Release) indicates that the active ingredient is released slowly over an extended period of time. This delivery system may help maintain a relatively stable concentration of the drug within the body, which supports the continuous management of symptoms.

This medication is primarily indicated for use in managing conditions such as certain chronic pain states and disorders where fluctuation in drug levels can be a concern. The sustained release form contributes to improving the convenience of the regimen, as it reduces the frequency of administration compared to standard immediate-release options, potentially aiding in patient adherence. It assists in achieving and sustaining therapeutic drug levels for a prolonged duration.

Modified-release formulations are subject to rigorous assessment to ensure their pharmacokinetic properties are suitable for the intended therapeutic use.

---

Quick Facts

• Therapeutic Focus: Assists in the management of specific chronic conditions.
• Benefit Profile: Supports sustained therapeutic control.
• Formulation Advantage: Contributes to a reduced dosing frequency.
• Clinical Goal: Aims to maintain stable drug concentrations for an extended period.

Regulatory References

1. EMA therapeutic overview for modified-release dosage forms

Eligibility Scope

Populations for whom use is allowed (as stated in label):

• Adults and Older Adults: The medication is established for use in the adult population, and studies have not shown unique problems limiting its usefulness in the elderly.
• Patients with Mild Hepatic Impairment: No dosage adjustment is formally recommended for patients with mild hepatic impairment (Child-Pugh score of 5–6).

Populations for whom use is not recommended:

• Patients with Severe Hepatic Impairment: Use is not recommended in patients with a Child-Pugh score of 10–15.
• Patients with Severe Renal Impairment: Use is not recommended in patients with a creatinine clearance less than 9 mL/min.
• Pediatric Population: Safety and efficacy have not been established for use in individuals under 18 years of age.

Populations for whom use is contraindicated:

• Patients with known hypersensitivity to galantamine hydrobromide or any excipients in the formulation.
• Patients with both significant renal and hepatic dysfunction are generally contraindicated.

Age-related eligibility rules:

• Pediatric Use: Safety and effectiveness are not established.
• Adult and Older Adult Use: Considered the established target population based on regulatory review.

Condition-specific eligibility rules:

• Moderate Hepatic or Renal Impairment: Use is restricted, and a lower maximum daily intake (not exceeding 16 mg/day) is generally specified in the official label.

Eligibility-related restrictions:

• Caution is advised for patients with cardiac conduction defects (e.g., sick sinus syndrome), severe pulmonary conditions (e.g., severe asthma), or a history of gastrointestinal ulcers or bladder outflow obstruction.

---

Connection to the Overall Eligibility Profile

The official regulatory documents define eligibility for Bergal SR by prohibiting its use in cases of known hypersensitivity or severe organ dysfunction. For populations with moderate hepatic or renal impairment, eligibility is conditional and requires a maximum daily dose restriction, as defined in the label. Use in the pediatric population is formally classified as not established, excluding this age group from standard use. The medicine is primarily established for use in the adult and older adult populations.

Interactions with other medicines and products

Bergal SR (Galantamine Hydrobromide) interaction patterns are documented according to established pharmacokinetic and pharmacodynamic profiles. The most significant pharmacokinetic interactions involve co-administration with medicines that inhibit the CYP2D6 or CYP3A4 metabolic enzymes, such as certain antidepressants (e.g., Paroxetine) or antifungals (e.g., Ketoconazole). Co-administration with these inhibitors may increase the systemic exposure (AUC) of Galantamine.

Pharmacodynamic interactions are relevant with medicinal products that share or oppose its cholinergic activity. Co-use with other cholinesterase inhibitors or cholinergic agonists may result in documented additive effects. Caution is also noted when administered alongside drugs that significantly slow the heart rate (e.g., certain beta-blockers or Digoxin), due to a potential for additive vagotonic effects. Conversely, Galantamine may reduce the activity of Anticholinergic Agents. Additionally, the drug is expected to exaggerate the neuromuscular blocking effects of succinylcholine-type agents.

Specific restrictions defined in regulatory documents include the administration condition that the Sustained-Release capsule must be taken once daily with the morning meal. Use is not recommended in patients with severe hepatic impairment or severe renal impairment due to the expected substantial decrease in drug clearance, leading to increased exposure. Known hypersensitivity to the active ingredient remains a formal contraindication.

Dual Mechanism: Enzyme Inhibition and Receptor Potentiation

The drug's primary mechanistic focus is the modulation of Central Cholinergic Neurotransmission through a dual action on two distinct biological targets. It acts as a competitive, reversible inhibitor of the Acetylcholinesterase (AChE) enzyme, which reduces the rate of Acetylcholine (ACh) breakdown. Simultaneously, the drug functions as an allosteric modulator of neuronal Nicotinic Acetylcholine Receptors (nAChRs), increasing the sensitivity and responsiveness of these receptors to the available ACh.

Mechanistic Cascade and Functional Augmentation

These complementary molecular actions initiate a cascade that alters signaling dynamics within the affected neural pathways. By reducing the rate of Acetylcholine breakdown and augmenting the functional response of its receptors, the mechanism results in a sustained elevation of synaptic Acetylcholine concentration and increased nAChR response. This stabilized signaling modulates the activity of central neural circuits, while the Sustained-Release (SR) formulation maintains the consistent drug concentration required for this continuous mechanistic activity.

How to Use Bergal SR: Official Administration Guidelines

Bergal SR (Galantamine Hydrobromide Sustained-Release Capsule) is administered strictly via the oral route and follows a controlled, gradual dosing structure. The sustained-release design necessitates a once-daily schedule, with administration recommended in the morning.

To ensure the intended release profile, the capsule must be swallowed whole and must not be crushed, broken, or chewed. The medicine should be taken preferably with food, and adequate fluid intake is recommended throughout the duration of use.

Dosage and Titration Protocol

Official use is structured by a mandatory, minimum four-week interval between dose increases. This titration principle is used to progress patients from the starting dose to the effective maintenance range. The dosage steps are clearly defined:

Dosing Step	Dose Strength	Frequency	Required Duration
Starting Dose	8 mg	Once daily	Minimum of four weeks
Initial Maintenance	16 mg	Once daily	Minimum of four weeks
Maximum Dose	24 mg	Once daily	Only after 16 mg is maintained

Special Use Conditions

Dosage Adjustments: For patients with moderate kidney or liver impairment, the maximum daily dose is restricted and should generally not exceed 16 mg. Use of the medicine is generally not recommended for those with severe impairment in either organ function.

Treatment Interruption: If a patient stops taking Bergal SR for a period greater than three consecutive days, the patient must return to the lowest initial dosage of 8 mg once daily. The entire dose titration process must then be repeated to re-establish the required therapeutic level.

Research evidence / Overview of studies for Bergal SR

Evidence for use in Mild to Moderate Alzheimer's Disease

This section will summarize the core research that was evaluated in adults diagnosed with mild to moderate Alzheimer's type dementia, a condition marked by functional limitations. The research documentation includes pivotal, short-term, placebo-controlled randomized clinical trials (RCTs). These studies monitored changes in key outcomes reflecting daily functioning or activity level, as well as outcomes related to systemic or functional imbalance measured by standardized cognitive and global clinical scales.

• Findings describe patterns observed in the studies over the typical three-to-six-month treatment period.
• Short-term trials reported how symptoms evolved in the observed populations, noting differences in measurement score changes on cognitive and global scales when comparing the treatment group to the placebo group.
• Systematic reviews highlight changes measured during the study period, noting a consistent variation in trajectory for cognitive decline measurements across the evidence.

Long-term studies and follow-up

This area research examined the evidence available over extended time intervals, including a dedicated two-year controlled trial and data collected from open-label extensions (where all participants received the active study medicine). This research examined outcomes over extended time intervals, and included studies exploring the durability of observed symptom patterns and the continuity of outcomes reflecting daily functioning or activity level for up to two years.

• The dedicated long-term randomized study describes patterns related to a difference in the rate of change in scores for functional capacity and cognitive measures over two years, compared to the continuous placebo group.
• The available data show patterns related to outcomes related to systemic or functional imbalance persisting over defined time intervals.

Evidence in related populations

This part of the overview was studied for specific populations, including those with Alzheimer's disease that also was associated with cerebrovascular components (often termed mixed dementia). It will outline the general characteristics of patient populations included in the main regulatory trials, providing context for how the results apply only to the populations studied.

• Trials primarily were evaluated in adults with confirmed mild to moderate Alzheimer’s type dementia, and subgroup findings are uncertain for many other specific comorbidities.
• Data for certain groups remain insufficient, particularly for patients with severe organ impairment or certain serious cardiovascular issues, as these individuals were typically excluded from the core controlled studies.

Evidence in comparison to other therapies

This section will summarize the available scientific literature, primarily meta-analyses, that studies explored the measured outcomes of this medicine against other approved therapies in the cholinesterase inhibitor class. The summary will focus on describing the overall consistency or variability across studies for these comparative findings.

• Available comparative research findings indicate that differences in measured outcomes related to systemic or functional imbalance between this medicine and other similar therapies appear to vary across studies, and consistent patterns across these comparisons are limited.
• The comparison research was observed in studies that measured changes in outcomes related to cognitive status and daily functioning across different treatment agents.

What is still uncertain about Bergal SR research

This final section will synthesize the known limitations and key evidence gaps documented in the scientific literature and regulatory assessments. Evidence is limited in several key areas.

• Long-term effects are not fully established beyond the two-year controlled trial period, as subsequent controlled follow-up durations were limited.
• Existing studies provide limited information for long-term outcomes regarding the medicine's potential to alter the underlying progressive pathology of the condition itself; the research was studied for symptomatic effects only.
• Data for certain groups remain insufficient, including those with advanced stages of the condition or specific, serious comorbidities.

Key Studies & References

1. Galantamine (Reminyl): Efficacy and Safety Review
2. Therapeutic Class Review: Acetylcholinesterase Inhibitors (for Alzheimer's Disease)

Common questions about Bergal SR (FAQ)

Q: What happens if I miss a dose of Bergal SR?

Regulatory documents specify a rule for treatment interruption. If the use of Bergal SR is stopped for a period greater than three consecutive days, official guidelines state that the patient must return to the lowest starting dosage. The entire dose escalation process is then required to be repeated, as described in official guidance.

Q: What happens if I stop taking Bergal SR suddenly?

Official regulatory analysis found that the abrupt withdrawal from effective dosages of the extended-release capsule was not associated with an increased frequency of adverse events. If treatment is interrupted for three days or more, official guidance specifies that a patient needs to restart at the lowest dosage and repeat the dose escalation process.

Q: What is the difference between Bergal SR and regular Bergal?

Bergal SR is the Sustained-Release (SR) formulation of the active ingredient, Galantamine. This design is engineered to release the medicine slowly throughout the day. The design supports a once-daily dosing schedule, as outlined in official administration guidelines. The regular (Immediate Release) version of the same medicine is typically taken twice a day.

Q: How long does Bergal SR stay in your system?

Pharmacokinetic data reviewed by regulatory bodies indicates that the active ingredient, Galantamine, has an elimination half-life of approximately 7 hours. The half-life is the calculated time required for the concentration of the medicine in the bloodstream to be reduced by half.

Q: Why is Bergal SR used for different conditions?

According to official regulatory bodies, Bergal SR is approved for the treatment of mild to moderate dementia of the Alzheimer's type. This is the single, established indication based on regulatory approval and documentation. Research has also examined its use in similar populations, such as those with mixed dementia.

Q: Does Bergal SR cause weight gain or loss?

Official product safety documents, which summarize clinical trial findings, list weight loss as a common documented side effect of the active ingredient, Galantamine.

Q: Is Bergal SR safe to use for a long time?

Research has examined the use of the medicine for extended time intervals to assess its profile. This includes a dedicated controlled trial that collected data for up to two years, and the safety profile generally remained consistent across the duration of these studies.

Q: Is Bergal SR known to interact with blood pressure medications?

Regulatory documents note that the medicine can affect heart rate. Due to this potential effect, caution is advised when the medicine is co-administered with other products that significantly slow the heart rate (e.g., certain beta-blockers) due to the potential for additive effects.

Q: Is it normal to feel tired after starting Bergal SR?

Regulatory summaries of reported effects indicate that dizziness and headache are common documented effects. Other symptoms, such as tiredness, fatigue, or unusual weakness, have also been reported in official safety information.

Q: Is Bergal SR habit-forming?

The medicine is classified by regulatory authorities as Not a controlled medication. This classification indicates that the medicine is not categorized as having a potential for abuse or dependency.

Q: Is Bergal SR a type of opioid?

No. The drug is classified as an Acetylcholinesterase Inhibitor (AChEI). This is a class of medicine that supports communication between nerve cells. It is not classified as an opioid.

Q: Can older adults use Bergal SR?

Yes, the medicine is established for use in the adult population, which includes older adults. Regulatory review of the available data has found no unique problems or limitations that restrict its usefulness specifically in the elderly population.

Q: Does Bergal SR cause any mental or mood changes?

Official regulatory summaries list adverse reactions that affect the nervous system and mood. These include difficulty falling asleep or depression. Other effects, such as anxiety or confusion, have been reported as signs preceding or during a seizure.

Q: Is there a generic version of Bergal SR available?

Yes. Regulatory records maintained by agencies like the FDA confirm that a generic version of the active ingredient, galantamine hydrobromide extended-release, is approved and available.

Q: What should I do if the side effects of Bergal SR are bothering me?

Authoritative health information indicates that a patient needs to inform their healthcare provider if side effects are experienced or if they become severe or do not go away.

Q: Does Bergal SR interact with herbal supplements like St. John's Wort?

The active ingredient is metabolized by specific liver enzymes. Regulatory guidelines indicate that patients need to inform their healthcare provider about all medicines, including prescription, nonprescription, and herbal products that are being taken, as a check for potential interactions.

Q: Has Bergal SR been approved in countries outside the US?

Yes. Regulatory approval for the active ingredient has been established in multiple regions globally, including the European Union, Canada, and Japan, in addition to the United States.

Q: Is it possible for Bergal SR to lose its effect over time?

Studies have examined the durability of the observed effect. Because the medicine is used to manage a progressive disease, the therapeutic benefits may decrease over time as the underlying condition advances and fewer target nerve cells remain functional.

Q: How often do I need follow-up appointments when taking Bergal SR?

Authoritative health guidelines specify that a patient needs to visit their care team for regular checks on their progress. This may include annual reviews to monitor the patient's condition and treatment.

Q: Is Bergal SR the first drug of its kind?

The medicine is described in the scientific literature as having a unique dual mechanism of action compared to other similar medicines in its class. It acts as both an enzyme inhibitor and a modulator of nerve receptors.

Q: Can men and women use Bergal SR equally?

Pharmacokinetic analysis indicates that the clearance of the active ingredient is approximately 20% lower in women than in men, which is attributed to differences in body weight. However, dosage adjustments are generally not specified based on gender alone, as the required dosage is individually determined.

Storage Conditions for Bergal SR

Bergal SR (Galantamine Hydrobromide Extended-Release Capsules) must be stored strictly according to official regulatory specifications to maintain product stability and integrity.

• Temperature: Store at Controlled Room Temperature, defined as 20 °C to 25 °C (68 °F to 77 °F), with limited excursions permitted.
• Protection: The medication must be kept from freezing and protected from excess heat, moisture, and direct light.
• Container: The capsules should remain in the original container and be kept tightly closed to ensure protection from moisture.
• Child Safety: Consistent with labeled requirements, the product must be stored out of the reach of children.

Disposal Instructions

Disposal of unused or expired Bergal SR must follow specific environmental protocols. Patients are instructed to consult a healthcare professional or pharmacist for guidance on how to properly discard the medicine. Disposal must be conducted in compliance with all applicable local and national waste regulations.